67 reports of this reaction
1.4% of all METHYLENE BLUE reports
#15 most reported adverse reaction
ALANINE AMINOTRANSFERASE INCREASED is the #15 most commonly reported adverse reaction for METHYLENE BLUE, manufactured by American Regent, Inc.. There are 67 FDA adverse event reports linking METHYLENE BLUE to ALANINE AMINOTRANSFERASE INCREASED. This represents approximately 1.4% of all 4,684 adverse event reports for this drug.
Patients taking METHYLENE BLUE who experience alanine aminotransferase increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALANINE AMINOTRANSFERASE INCREASED is a less commonly reported adverse event for METHYLENE BLUE, but still significant enough to appear in the safety profile.
In addition to alanine aminotransferase increased, the following adverse reactions have been reported for METHYLENE BLUE:
The following drugs have also been linked to alanine aminotransferase increased in FDA adverse event reports:
ALANINE AMINOTRANSFERASE INCREASED has been reported as an adverse event in 67 FDA reports for METHYLENE BLUE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALANINE AMINOTRANSFERASE INCREASED accounts for approximately 1.4% of all adverse event reports for METHYLENE BLUE, making it a notable side effect.
If you experience alanine aminotransferase increased while taking METHYLENE BLUE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.